ADVANCED SOLID TUMOR

This early-stage study tested a new drug called BRY805 in adults with advanced solid tumors that hadn't responded to standard treatments. The main goal was to check the drug's safety, find the right dose, and see if it showed any signs of fighting cancer. The trial was terminated…

This is an early-stage study to test the safety and find the right dose of a new drug called BGB-B3227 for people with advanced or metastatic solid tumors. The drug will be tested both by itself and in combination with another cancer drug, tislelizumab. The main goals are to see …

This study tested the safety and effectiveness of combining two drugs, APG-1387 and toripalimab, for people with advanced solid tumors that had stopped responding to standard treatments. The trial involved about 40 participants with specific cancers, including colorectal cancer, …

This early-stage study tested a new oral cancer drug called NUV-868, both alone and combined with existing medications (olaparib or enzalutamide), in adults with advanced solid tumors. The trial aimed to find safe doses and see if these treatments could help control cancers that …

This study tested a new drug, PRT3789, combined with an existing immunotherapy (pembrolizumab) for people with advanced or spreading cancers that have a specific genetic change called a SMARCA4 mutation. The goal was to see if this combination was safe and could shrink or control…

This early-stage trial tested a personalized treatment called Tumor-Infiltrating Lymphocyte (TIL) therapy for adults with advanced solid tumors that hadn't responded to standard treatments. Doctors collected immune cells from a patient's own tumor, grew large numbers of them in a…

This early-stage clinical trial tested a new drug called DCC-3084, both alone and combined with other cancer therapies, for people with advanced solid tumors driven by specific genetic mutations. The study aimed to find a safe dose and see if the treatment could shrink tumors in …

This early-stage study tested a new drug called RiMO-401, injected directly into tumors along with radiation therapy, for people with advanced cancers. The main goal was to find a safe dose and check for side effects in a small group of 5 participants. The study was terminated ea…

This was an early safety study testing a new oral drug called MRTX0902, both alone and combined with another cancer drug (adagrasib), in people with advanced solid tumors that have specific genetic mutations in the KRAS pathway. The main goals were to find safe doses and see how …

This early-stage study tested a new oral drug called PRT7732 in people with advanced or metastatic solid tumors that have a specific genetic change (SMARCA4 mutation). The main goals were to find a safe dose, see how the body processes the drug, and look for early signs that it m…

This early-stage study tested the safety of an experimental treatment called VAXINIA, which is a modified virus designed to infect and kill cancer cells. It was given to 66 adults with advanced solid tumors that had spread and stopped responding to other treatments. The virus was…

This study tested whether combining two immunotherapy drugs (SON-1010 and atezolizumab) could help control advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The trial involved 40 patients with advanced solid tumors, including those with platin…

This early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…

This early-stage study aimed to test the safety of a new drug called M9466 when combined with standard chemotherapy for advanced solid tumors and colorectal cancer. The trial was designed for people whose cancer had progressed despite standard treatments. However, the study was t…

This early-stage study tested a new oral drug, RP-6306, given alongside a standard chemotherapy regimen (FOLFIRI) in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose, understand side effects, and see…

This early-stage trial tested the safety of an experimental drug called RP-3467, both alone and combined with an existing cancer drug (olaparib), in adults with advanced solid tumors. The study aimed to find the highest safe dose and understand how the body processes the drug. It…

This first-in-human study tested a new cancer drug called PHN-010 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, determine the right dose, and see if it could shrink tumors. The trial incl…

This early-phase study tested a new experimental drug designed to stimulate the body's immune system to fight cancer. The drug was injected directly into tumors in adults with advanced solid cancers that had stopped responding to standard treatments. Researchers aimed to find a s…

This was an early safety study for a new oral cancer drug called RP-1664. It tested the drug in 29 people with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see how the drug behaved in the body, but the trial wa…

This was an early-stage study to test a new cancer drug called LB101 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked for early signs that the drug …

This early-stage study tested a new combination drug called JSKN033 in patients with advanced solid tumors that have spread and express the HER2 protein. The trial aimed to find a safe dose and see if the drug could help control cancer growth. It involved a small group of patient…

This study tested an oral medication called ART0380 for people with advanced or metastatic solid tumors that have specific weaknesses in their DNA repair system. It aimed to see if the drug could shrink tumors and was safe. The trial was designed for 36 participants, including th…

This study aimed to understand how an experimental cancer drug travels through the body and how much of it reaches tumors. It used special PET scans to track a tiny radioactive tag attached to the drug in a small group of patients with advanced solid tumors. The main goal was to …